Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ:ADXS opened at $0.03 on Tuesday. The stock has a 50 day moving average of $0.05 and a 200 day moving average of $0.11. The company has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.81. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.